AstraZeneca’s Lynparza shows significant PFS benefit in ovarian cancer patients
A phase III trial designed to evaluate the efficacy of AstraZeneca’s Lynparza (olaparib) tablets as maintenance treatment for women with BRCA-mutated metastatic ovarian cancer has demonstrated significant progression-free survival (PFS) benefit.
